Tech Company Financing Transactions
Tarsa Therapeutics Funding Round
Tarsa Therapeutics, based in Philadelphia, secured $15.5 million from private investors.
Transaction Overview
Company Name
Announced On
4/22/2011
Transaction Type
Debt
Amount
$15,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. Amount may include options, warrants or other rights to acquire other securities. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8 Penn Center 1628 John F. Kennedy Blvd. 1400
Philadelphia, PA 19103
USA
Philadelphia, PA 19103
USA
Phone
Website
Email Address
Overview
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Brand
Chief Medical Officer
David Krause
Chief Scientific Officer
James Gilligan
VP - Regulatory Affairs
Nicholas LaBella
Browse more venture capital transactions:
Prev: 4/22/2011: Mersana Therapeutics venture capital transaction
Next: 4/22/2011: Oncoscope venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs